Abstract:The authors report the crystal structure of the β2 adrenergic receptor in complex with compound 15, an allosteric modulator that binds to an alternative binding pocket. Most of the crystal structures of G-protein-coupled receptors (GPCRs) reported to date have been solved in complex with ligands bound to their orthosteric site, the primary binding site of a receptor. Recently, however, several studies have reported that certain chemokine receptors contain an allosteric pocket on their intracellular surface that could be targeted to interfere with receptor signalling. Brian Kobilka and colleagues report the crystal structure of the β2-adrenergic receptor in complex with compound 15, an allosteric modulator that binds to a similar site to the chemokine receptors, showing that this feature may be conserved among a number of GPCRs. Typically, beta-blockers, which are widely prescribed drugs for cardiac arrhythmia, block the action of the β-adrenergic receptors from the orthosteric site. This study shows how compound 15, the first allosteric beta-blocker, modulates agonist binding and signalling from its intracellular binding site. G-protein-coupled receptors (GPCRs) pose challenges for drug discovery efforts because of the high degree of structural homology in the orthosteric pocket, particularly for GPCRs within a single subfamily, such as the nine adrenergic receptors. Allosteric ligands may bind to less-conserved regions of these receptors and therefore are more likely to be selective. Unlike orthosteric ligands, which tonically activate or inhibit signalling, allosteric ligands modulate physiologic responses to hormones and neurotransmitters, and may therefore have fewer adverse effects. The majority of GPCR crystal structures published to date were obtained with receptors bound to orthosteric antagonists, and only a few structures bound to allosteric ligands have been reported. Compound 15 (Cmpd-15) is an allosteric modulator of the β2 adrenergic receptor (β2AR) that was recently isolated from a DNA-encoded small-molecule library1. Orthosteric β-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in the world and Cmpd-15 is the first allosteric beta-blocker. Cmpd-15 exhibits negative cooperativity with agonists and positive cooperativity with inverse agonists. Here we present the structure of the β2AR bound to a polyethylene glycol-carboxylic acid derivative (Cmpd-15PA) of this modulator. Cmpd-15PA binds to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8. A comparison of this structure with inactive- and active-state structures of the β2AR reveals the mechanism by which Cmpd-15 modulates agonist binding affinity and signalling.

Small Molecule Modulators of Beta-arrestins

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

Phospho-selective Mechanisms of Arrestin Conformations and Functions Revealed by Unnatural Amino Acid Incorporation and 19F-NMR

A small molecule enhances arrestin-3 binding to the β2-adrenergic receptor

Negative Allosteric Modulation of Arrestin Recruitment to the Β2‐adrenergic Receptor

Mechanism of Β 2 AR Regulation by an Intracellular Positive Allosteric Modulator

Abstract P2154: A Novel Allosteric Modulator of the Β 1 AR Identified by DNA-encoded Small Molecule Library Screening Demonstrates Unique Pharmacology and Function

A New Series of Gs‐ and Β‐arrestin‐biased Β2‐adrenoceptor Agonists

Therapeutic Potential of Targeting ß-Arrestin

Molecular basis of β-arrestin coupling to formoterol-bound β1-adrenoceptor

Location-biased β-arrestin conformations direct GPCR signaling

β-arrestin and β-adrenergic Receptor

Signal transduction at GPCRs: Allosteric activation of the ERK MAPK by β-arrestin

An Allosteric Modulator Binds to a Conformational Hub in the Β2 Adrenergic Receptor.

Mechanism of Intracellular Allosteric Β2ar Antagonist Revealed by X-ray Crystal Structure

Allosteric mechanisms underlie GPCR signaling to SH3-domain proteins through arrestin

Molecular insights into atypical modes of β-arrestin interaction with seven transmembrane receptors

LIPIDS MODULATE THE DYNAMICS OF GPCR:β-ARRESTIN INTERACTION

Discovery Of Beta-Arrestin-Biased Dopamine D-2 Ligands For Probing Signal Transduction Pathways Essential For Antipsychotic Efficacy

Manifold Roles of Β-Arrestins in GPCR Signaling Elucidated with Sirna and CRISPR/Cas9.